Cargando…

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions

Transfusional iron overload is a major target in the care of patients with transfusion-dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver, heart, and endocrine organs leading to a wide array of complications. In this review, we summarize the characteristics of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saliba, Antoine N, Harb, Afif R, Taher, Ali T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476479/ https://www.ncbi.nlm.nih.gov/pubmed/26124688 http://dx.doi.org/10.2147/JBM.S72463

Ejemplares similares

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

How I treat non-transfusion-dependent β-thalassemia
por: Saliba, Antoine N., et al.
Publicado: (2023)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
por: Sleiman, Joseph, et al.
Publicado: (2018)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy
por: Farmaki, Kallistheni, et al.
Publicado: (2008)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia
por: Goulas, Vasilis, et al.
Publicado: (2012)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
por: Bayanzay, Karim, et al.
Publicado: (2016)

Thalassemia in the emergency department: special considerations for a rare disease
por: Saliba, Antoine N., et al.
Publicado: (2020)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives [Corrigendum]
Publicado: (2016)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

Topical Iron Chelator Therapy: Current Status and Future Prospects
por: Ramadoss, Tanya, et al.
Publicado: (2023)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Pituitary iron and factors predictive of fertility status in transfusion-dependent thalassemia
por: Singer, Sylvia T., et al.
Publicado: (2020)

Iron overload status in patients with non-transfusion-dependent thalassemia in China
por: Huang, Yumei, et al.
Publicado: (2022)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Non-transfusion dependent hemoglobin E/β thalassemia had high prevalence of vitamin D deficiency than more severe patients who received regular blood transfusion and iron chelation therapy
por: Nakavachara, Pairunyar, et al.
Publicado: (2013)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Setting for “Normal” Serum Ferritin Levels in Patients with Transfusion-Dependent Thalassemia: Our Current Strategy
por: Spasiano, Anna, et al.
Publicado: (2021)

Coagulopathy in Beta-Thalassemia: Current Understanding and Future Perspectives
por: Cappellini, M. Domenica, et al.
Publicado: (2009)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis
por: Huang, Yumei, et al.
Publicado: (2019)

Pulmonary function in patients with transfusion-dependent thalassemia and its associations with iron overload
por: Chan, Kate C., et al.
Publicado: (2023)

Pulmonary Functions in Transfusion-Dependent Thalassemia
por: Chandra, Jagdish, et al.
Publicado: (2022)

A Multicenter ICET-A Study on Age at Menarche and Menstrual Cycles in Patients with Transfusion-Dependent Thalassemia (TDT) who Started Early Chelation Therapy with Different Chelating Agents
por: Di Maio, Salvatore, et al.
Publicado: (2023)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia
por: Reddy, Paavani S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1tb06tjpvogfstlsu5hdhg3fk3